Document is current
Any future updates will be listed below
-
Authors
Fiskus, Warren https://orcid.org/0000-0002-7343-6214
Boettcher, Steffen https://orcid.org/0000-0001-9937-0957
Daver, Naval https://orcid.org/0000-0001-7103-373X
Mill, Christopher P.
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Birdwell, Christine E.
Davis, John A.
Takahashi, Koichi https://orcid.org/0000-0002-8027-9659
Kadia, Tapan M. https://orcid.org/0000-0002-9892-9832
DiNardo, Courtney D.
Jin, Qi
Qi, Yuan
Su, Xiaoping
McGeehan, Gerard M.
Khoury, Joseph D. https://orcid.org/0000-0003-2621-3584
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Bhalla, Kapil N. https://orcid.org/0000-0001-5209-5126
- License Information
-
More Information
Article History
Received: 8 November 2021
Revised: 10 December 2021
Accepted: 16 December 2021
First Online: 11 January 2022
Competing interests
: Gerard M. McGeehan is an employee of Syndax Pharmaceuticals. Benjamin L. Ebert has received research funding from Celgene, Deerfield, Novartis, and Calico; and he is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, Skyhawk Therapeutics, and Exo Therapeutics, none of which are directly related to the content of this paper. The remaining authors declare no competing interests.
